Mentopin Hustenlöser (Acetylcysteine)

Acetylcysteine acts by cleaving disulfide bonds in mucus glycoproteins, breaking down the polymeric network that makes mucus viscous. This reduction in viscosity improves mucociliary clearance, allowing patients to expectorate secretions more easily and relieve cough.

The appropriate dose of Mentopin Hustenlöser is determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, and clinical condition. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for acetylcysteine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mentopin Hustenlöser.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Acetylcysteine differs from other mucolytics such as carbocisteine by directly breaking disulfide bonds in mucus, offering a rapid reduction in viscosity. Carbocisteine works mainly by modifying mucus synthesis. Clinical choice depends on the specific indication, patient tolerance, and physician preference.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures to maintain stability. Keep out of reach of children.

Mentopin Hustenlöser is intended for oral use. If supplied as a liquid, it should be measured with a calibrated device and taken as directed. If supplied as tablets or granules, they should be swallowed with water unless otherwise instructed by a healthcare professional.

The most serious adverse reactions include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, bronchospasm (particularly in asthmatic patients), and rare hepatic enzyme elevations. Any signs of severe allergic reaction or respiratory distress require immediate medical attention.

Mentopin Hustenlöser should be avoided in individuals with known hypersensitivity to acetylcysteine or any excipients in the formulation. Patients with severe renal impairment, uncontrolled asthma, or those taking contraindicated medications (e.g., certain carbapenem antibiotics) should consult a healthcare professional before use.